左西孟旦与脓毒症或脓毒性休克患者死亡率的相关性:系统评价与Meta分析
该系统评价与Meta分析检索PubMed、Embase、Web of Science和Cochrane Library(建库至2022年10月1日),纳入11项随机对照试验共1044例脓毒症或脓毒性休克患者,评估左西孟旦的疗效与安全性。主要终点28天死亡率在左西孟旦组为34.9%、对照组为36.2%,组间无统计学差异(OR 0.93,95%CI 0.72-1.2,P=0.57,I²=0%)。SOFA评分亦无统计学差异,但脓毒性休克患者的心功能与血清乳酸水平改善,左西孟旦组不良反应似乎更多。结论认为左西孟旦的使用与28天死亡率和SOFA评分无关联,尽管心功能和血清乳酸有统计学显著改善。
要点
- 11项RCT共1044例脓毒症或脓毒性休克患者,左西孟旦组28天死亡率34.9% vs 对照组36.2%,OR 0.93(95%CI 0.72-1.2),P=0.57,I²=0%,无统计学差异。
- 左西孟旦组与对照组SOFA评分无统计学差异。
- 脓毒性休克患者的心功能和血清乳酸水平在左西孟旦治疗后改善。
- 左西孟旦组不良反应似乎更多,安全性结局包括快速性心律失常和总不良反应发生率。
- 试验序贯分析校正后CI为0.6-1.42。
适用人群与场景
- 脓毒症或脓毒性休克患者(纳入11项随机对照试验,共1044例)
研究设计与关键结果
- 研究类型:系统评价与Meta分析,纳入11项随机对照试验,共1044例脓毒症或脓毒性休克患者。
- 主要终点28天死亡率:左西孟旦组34.9% vs 对照组36.2%,OR 0.93(95%CI 0.72-1.2),P=0.57,I²=0%,组间无统计学差异;试验序贯分析校正后CI为0.6-1.42。
- SOFA评分:左西孟旦组与对照组无统计学差异。
- 次要终点:脓毒性休克患者的心功能指标和血清乳酸水平(治疗最初24小时内变化)改善。
- 安全性:快速性心律失常和总不良反应发生率在左西孟旦组似乎更高。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入11项随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,左西孟旦的使用与脓毒症或脓毒性休克患者的28天死亡率和SOFA评分无关联,尽管心功能和血清乳酸有统计学显著改善;原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Levosimendan is increasingly being used in patients with sepsis or septic shock because of its potential to improve organ function and reduce mortality. We aimed to determine if levosimendan can reduce mortality in patients with sepsis or septic shock via meta-analysis.
EVIDENCE SOURCES AND STUDY SELECTION: We comprehensively searched the PubMed, Embase, Web of Science, and Cochrane Library databases from inception through 1 October 2022. Literature evaluating the efficacy of levosimendan in patients with sepsis or septic shock was included.
DATA EXTRACTION AND OUTCOME MEASUREMENTS: Two reviewers extracted data and assessed study quality. A meta-analysis was performed to calculate an odds ratio (OR), 95% confidence intervals (CI), and P -values for 28-day mortality (primary outcome). Secondary outcomes included changes in indexes reflecting cardiac function before and after treatment, changes in serum lactate levels in the first 24 h of treatment, and the mean SOFA score during the study period. Safety outcomes included rates of tachyarrhythmias and total adverse reactions encountered with levosimendan.
RESULTS: Eleven randomized controlled trials were identified, encompassing a total of 1044 patients. After using levosimendan, there was no statistical difference between groups for 28-day mortality (34.9% and 36.2%; OR: 0.93; 95% CI [0.72-1.2]; P = 0.57; I 2 = 0%; trial sequential analysis-adjusted CI [0.6-1.42]) and sequential organ failure assessment (SOFA) score, and more adverse reactions seemed to occur in the levosimendan group, although the septic shock patient's heart function and serum lactate level improved.
CONCLUSION: There was no association between the use of levosimendan and 28-day mortality and SOFA scores in patients with septic shock, though there was statistically significant improvement in cardiac function and serum lactate.
参考来源
- Ge Z, Gao Y, Lu X, et al. The association between levosimendan and mortality in patients with sepsis or septic shock: a systematic review and meta-analysis. Eur J Emerg Med. 2023. PMID: 38015719. doi:10.1097/MEJ.0000000000001105
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。